AU2016312610B2 - Methods for stem cell transplantation - Google Patents

Methods for stem cell transplantation Download PDF

Info

Publication number
AU2016312610B2
AU2016312610B2 AU2016312610A AU2016312610A AU2016312610B2 AU 2016312610 B2 AU2016312610 B2 AU 2016312610B2 AU 2016312610 A AU2016312610 A AU 2016312610A AU 2016312610 A AU2016312610 A AU 2016312610A AU 2016312610 B2 AU2016312610 B2 AU 2016312610B2
Authority
AU
Australia
Prior art keywords
cells
day
cell
administering
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016312610A
Other languages
English (en)
Other versions
AU2016312610A1 (en
Inventor
Lawrence S. Lamb
Shin Mineishi
Ayman SAAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU2016312610A1 publication Critical patent/AU2016312610A1/en
Application granted granted Critical
Publication of AU2016312610B2 publication Critical patent/AU2016312610B2/en
Priority to AU2023202946A priority Critical patent/AU2023202946A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2016312610A 2015-08-25 2016-08-25 Methods for stem cell transplantation Active AU2016312610B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202946A AU2023202946A1 (en) 2015-08-25 2023-05-11 Methods for stem cell transplantation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562209721P 2015-08-25 2015-08-25
US62/209,721 2015-08-25
PCT/US2016/048738 WO2017035375A1 (en) 2015-08-25 2016-08-25 Methods for stem cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202946A Division AU2023202946A1 (en) 2015-08-25 2023-05-11 Methods for stem cell transplantation

Publications (2)

Publication Number Publication Date
AU2016312610A1 AU2016312610A1 (en) 2018-04-12
AU2016312610B2 true AU2016312610B2 (en) 2023-02-16

Family

ID=58101080

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016312610A Active AU2016312610B2 (en) 2015-08-25 2016-08-25 Methods for stem cell transplantation
AU2023202946A Pending AU2023202946A1 (en) 2015-08-25 2023-05-11 Methods for stem cell transplantation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202946A Pending AU2023202946A1 (en) 2015-08-25 2023-05-11 Methods for stem cell transplantation

Country Status (10)

Country Link
US (2) US20190183930A1 (enExample)
EP (2) EP4458953A3 (enExample)
JP (2) JP7105188B2 (enExample)
KR (2) KR20180041229A (enExample)
CN (2) CN108025023A (enExample)
AU (2) AU2016312610B2 (enExample)
CA (1) CA2996522A1 (enExample)
ES (1) ES2984387T3 (enExample)
IL (1) IL257678B2 (enExample)
WO (1) WO2017035375A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180041229A (ko) * 2015-08-25 2018-04-23 유에이비 리서치 파운데이션 줄기 세포 이식을 위한 방법
CN117298268A (zh) * 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
WO2018107134A1 (en) 2016-12-09 2018-06-14 The Uab Research Foundation Chimeric chlorotoxin receptors
AU2018234827B2 (en) * 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
WO2018229218A1 (en) * 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd25 adc
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
EP3856206A1 (en) * 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
KR20200145328A (ko) 2019-06-21 2020-12-30 안혜빈 자동 물분사 칠판지우개
CN115175688A (zh) * 2019-11-05 2022-10-11 耶达研究及发展有限公司 在数个t细胞介导的自身免疫性疾病的治疗中的数个否决细胞的用途
WO2025122271A1 (en) * 2023-12-08 2025-06-12 IN8bio, Inc. Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361975T1 (de) * 1993-05-17 2007-06-15 Yeda Res & Dev Tiermodell für hepatitis-virus infektion
CA2360046A1 (en) * 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
US7078034B2 (en) * 1999-01-28 2006-07-18 Palmetto Health Alliance In vitro activated γ δ lymphocytes
WO2003012060A2 (en) * 2001-08-01 2003-02-13 Jewish Hospital Healthcare Services, Inc. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
EP2268293A2 (en) * 2008-07-17 2011-01-05 Smt. G R Doshi And Smt. K M Mehta Institute Of Kidney Diseases And Research Centre Stem cell composition for inducing transplant tolerance
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
EP2686417B1 (de) * 2011-03-17 2016-06-08 Miltenyi Biotec GmbH Tcralpha/beta-depletierte zellpräparationen
WO2012156958A2 (en) * 2011-05-19 2012-11-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
EP2717887B1 (en) * 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
EP2785743B1 (en) 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
US10434121B2 (en) * 2011-12-22 2019-10-08 Yeda Research And Development Co. Ltd. Combination therapy for a stable and long term engraftment using specific protocols for T/B cell depletion
CA2926859A1 (en) * 2013-10-25 2015-04-30 Board Of Regents, The University Of Texas System Polyclonal gamma delta t cells for immunotherapy
CN103834615A (zh) * 2014-03-27 2014-06-04 叶永清 一种适用于培养γδT细胞的无血清培养基
KR20180041229A (ko) * 2015-08-25 2018-04-23 유에이비 리서치 파운데이션 줄기 세포 이식을 위한 방법
CA3033876A1 (en) * 2016-08-18 2018-02-22 The Uab Research Foundation Compositions and methods for cancer immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. RÅDESTAD ET AL, J IMMUNOL. RES., 2014;2014:578741. doi:10.1155/2014/578741 *

Also Published As

Publication number Publication date
CN115137752A (zh) 2022-10-04
US20190183930A1 (en) 2019-06-20
EP3340997A1 (en) 2018-07-04
EP3340997B1 (en) 2024-02-14
CN108025023A (zh) 2018-05-11
ES2984387T3 (es) 2024-10-29
JP2022133453A (ja) 2022-09-13
KR20250048489A (ko) 2025-04-08
EP4458953A2 (en) 2024-11-06
AU2023202946A1 (en) 2023-06-01
JP7105188B2 (ja) 2022-07-22
KR20180041229A (ko) 2018-04-23
NZ740901A (en) 2024-12-20
WO2017035375A1 (en) 2017-03-02
CA2996522A1 (en) 2017-03-02
IL257678B1 (en) 2023-12-01
AU2016312610A1 (en) 2018-04-12
EP4458953A3 (en) 2025-01-22
JP2018525417A (ja) 2018-09-06
IL257678B2 (en) 2024-04-01
EP3340997A4 (en) 2019-03-06
IL257678A (en) 2018-04-30
US20220265720A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20220265720A1 (en) Methods for stem cell transplantation
Chang et al. Strategies for enhancing and preserving anti-leukemia effects without aggravating graft-versus-host disease
Serody et al. Comparison of granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood progenitor cells and G-CSF--stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation
EP2663332B1 (en) Enhancement of allogeneic hematopoietic stem cell transplantation
WO2013078392A1 (en) Methods and compositions involving induced senescent cells for cancer treatment
Bader et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells
Lundqvist et al. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions
JP6802150B2 (ja) がん治療のための免疫療法
Leung et al. Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies
Song et al. Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients
HK1257636A1 (en) Methods for stem cell transplantation
HK1257636B (en) Methods for stem cell transplantation
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
US20100129329A1 (en) METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION
Fassas et al. Separating graft-versus-tumor from graft-versus-host reactions
Greiner et al. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell
Micallef et al. A cost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization
Stankevich et al. Experience of clinical mesenchymal stem cells (MSCs) usage for prophylaxis and GVHD treatment in patients undergoing allo-HSCT
Kolb et al. W Zhao, JJ Li, DY Cao et al.,“Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis" World Journal of Gastroenterology, vol. 18, no. 10, pp. 1048–1058
BLOOD et al. Naoto T. Ueno, Gabriel N. Hortobagyi, Richard E.
Ferrara et al. Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects
Spitzer et al. GRAFT-VERSUS-HOST DISEASE: NEW PERSPECTIVES ON PATHOBIOLOGY AND THERAPY
Reikvam et al. Anticancer Immunotherapy in Combination with Proapoptotic Therapy-Possible Therapeutic Strategies for Enhancement of Anticancer Immune Reactivity in Autologous Immunocompetent Cells and After Allogeneic Stem Cell Transplantation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)